DESVENLAFAXINE SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Desvenlafaxine Succinate patents expire, and what generic alternatives are available?
Desvenlafaxine Succinate is a drug marketed by Actavis Labs Fl, Alembic, Hikma, Intellipharmaceutics, Lupin Ltd, Norvium Bioscience, Rubicon, Yichang Humanwell, and Zydus Pharms. and is included in ten NDAs.
The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desvenlafaxine Succinate
A generic version of DESVENLAFAXINE SUCCINATE was approved as desvenlafaxine succinate by ALEMBIC on June 29th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DESVENLAFAXINE SUCCINATE?
- What are the global sales for DESVENLAFAXINE SUCCINATE?
- What is Average Wholesale Price for DESVENLAFAXINE SUCCINATE?
Summary for DESVENLAFAXINE SUCCINATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 10 |
| Finished Product Suppliers / Packagers: | 20 |
| Raw Ingredient (Bulk) Api Vendors: | 44 |
| Clinical Trials: | 40 |
| Patent Applications: | 309 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DESVENLAFAXINE SUCCINATE |
| What excipients (inactive ingredients) are in DESVENLAFAXINE SUCCINATE? | DESVENLAFAXINE SUCCINATE excipients list |
| DailyMed Link: | DESVENLAFAXINE SUCCINATE at DailyMed |
Recent Clinical Trials for DESVENLAFAXINE SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Seoul National University Hospital | Phase 4 |
| Seoul National University Bundang Hospital | Phase 4 |
Pharmacology for DESVENLAFAXINE SUCCINATE
Medical Subject Heading (MeSH) Categories for DESVENLAFAXINE SUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for DESVENLAFAXINE SUCCINATE
Paragraph IV (Patent) Challenges for DESVENLAFAXINE SUCCINATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 25 mg | 021992 | 1 | 2015-05-08 |
| PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 50 mg and 100 mg | 021992 | 12 | 2012-02-29 |
US Patents and Regulatory Information for DESVENLAFAXINE SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Labs Fl | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204065-001 | Jul 29, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rubicon | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204028-001 | Jun 29, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204020-001 | Oct 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204082-002 | Aug 28, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alembic | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204003-003 | Sep 14, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lupin Ltd | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204172-003 | Apr 13, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
